Overall age-adjusted mortality rates have fallen, but the poorest parts of the world aren’t sharing in the benefits.

The most read stories this past month detailed the passing of Dimitrios Karmpaliotis and news on Evoque and COVID-19.

The study led to questions about whether patients would be best served by being treated at high-volume centers of excellence.

In EARLY TAVR, intervention improved outcomes over waiting in patients with class II or no indications for AVR consideration.

Labels for the Pfizer and Moderna shots, which already caution about myocarditis and pericarditis, will more strongly stress ...

The findings highlight the importance of having an EP versed in lead management on the heart valve team, one expert says.

In DETECT AS, the passive notifications improved rates of AVR and boosted survival, with bigger gains in women.

In an early look at SCOT-HEART 2, CCTA led more primary-prevention patients to make changes to reduce their risk of CVD.

The procedures are not mutually exclusive, however, and should be considered on a patient-by-patient basis, a researcher says ...

Acute MI mortality has fallen, yet deaths from other diseases, including heart failure and hypertension, are on the rise.

Cardiologists need to embrace the wave of new drugs, say experts, particularly since they can reduce the risk of CVD.

This month: pharmacy’s growing CICU role, arrhythmias’ impact on pregnancy, Life’s Essential 8 in practice, and more.